CorMedix Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRMD research report →
About the company
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution.
- CEO
- Joseph Todisco
- IPO
- 2010
- Employees
- 64
- HQ
- Berkeley Heights, NJ, US
Price Chart
- Market Cap
- $686.45M
- P/E
- 3.68
- P/S
- 1.72
- P/B
- 1.59
- EV/EBITDA
- 3.07
- Div Yield
- 0.00%
- Gross Margin
- 85.83%
- Op Margin
- 48.41%
- Net Margin
- 45.25%
- ROE
- 50.38%
- ROIC
- 27.59%
- Revenue
- $311.71M · 617.03%
- Net Income
- $163.06M · 1009.40%
- EPS
- $2.25 · 850.00%
- Op Income
- $150.14M
- FCF YoY
- 440.60%
- 52W High
- $14.96
- 52W Low
- $6.13
- 50D MA
- $8.11
- 200D MA
- $8.95
- Beta
- 1.48
- Avg Volume
- 1.31M
Get TickerSpark's AI analysis on CRMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 4, 26 | Zelnick Kaufman Beth | other | 36,006 |
| Feb 4, 26 | Hurlburt Elizabeth | other | 36,006 |
| Feb 4, 26 | Todisco Joseph | other | 77,156 |
| Jan 23, 26 | Blum Susan | other | 72,820 |
| Jan 23, 26 | Blum Susan | other | 9,767 |
| Jan 23, 26 | Zelnick Kaufman Beth | other | 72,820 |
| Jan 23, 26 | Zelnick Kaufman Beth | other | 8,803 |
| Jan 23, 26 | Hurlburt Elizabeth | other | 93,010 |
| Jan 23, 26 | Hurlburt Elizabeth | other | 10,778 |
| Jan 23, 26 | Todisco Joseph | other | 225,900 |
Our CRMD coverage
Recent articles, reports, and earnings notes.
No research on CRMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRMD report →Similar companies
Peers in the same neighborhood.